HUB tumor organoids for oncology drug development
Despite robust indications of activity in existing preclinical models, such as cell lines and animal models, around 95% of new anticancer drugs fail to reach patients. The high attrition rate in cancer drug development has been attributed to poor translatability of preclinical models. Therefore, it has become clear that advanced preclinical models – directly derived from patient tissue and easily expandable in the lab – are needed to improve drug discovery and development.
This fact sheet explores how patient-derived organoids can capture the complexity of cancer and predict patient response to treatment in the clinic.
This content was provided by HUB Organoids.
